Estimating and interpreting the pharmacokinetic profiles of
individual patients with hemophilia A or B using a population
pharmacokinetic approach: communication from the SSC of the
ISTH

J 2017

Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH

IORIO, A., V. BLANCHETTE, Jan BLATNÝ, P. COLLINS, K. FISCHER et. al.

Basic information

Original name

Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH

Authors

IORIO, A., V. BLANCHETTE, Jan BLATNÝ, P. COLLINS, K. FISCHER and E. NEUFELD

Edition

Journal of Thrombosis and Haemostasis, Hoboken, Wiley, 2017, 1538-7933

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.899

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1111/jth.13867

UT WoS

000417211100022

Keywords in English

hemophilia A; hemophilia B

Abstract

V originále

The ISTH SSC on Factor VIII/IX has previously issued guidelines for studies assessing the pharmacokinetics (PK) of factor concentrates [1, 2]. It suggested drawing 10 or 11 blood samples over a period of 32-48 h or 50-72 h, after infusing 25-50 IU kg-1 or 50-75 IU kg-1, respectively, for FVIII or FIX, in cohorts of 12-15 patients with a crossover design. Such PK studies are not ideal for tailoring the treatment of individual patients, mostly because of the requirement for several blood samples. Owing to broad interindividual variation, the individual disposition of FVIII and FIX cannot be predicted from morphometric characteristics and average PK parameters, but requires empirical assessment in each individual [3-6]. Previous guidance of this ISTH SSC described the PK methodology for the prediction of individual trough levels of FVIII [7]. The present communication, building on recent advances in the population pharmacokinetics (PopPK) of FVIII and FIX [8], adds to the former documents.

Citovat

IORIO, A., V. BLANCHETTE, Jan BLATNÝ, P. COLLINS, K. FISCHER and E. NEUFELD. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. Hoboken: Wiley, 2017, vol. 15, No 12, p. 2461-2465. ISSN 1538-7933. Available from: https://dx.doi.org/10.1111/jth.13867.

@article{1399350,
   author = {Iorio, A. and Blanchette, V. and Blatný, Jan and Collins, P. and Fischer, K. and Neufeld, E.},
   article_location = {Hoboken},
   article_number = {12},
   doi = {http://dx.doi.org/10.1111/jth.13867},
   keywords = {hemophilia A; hemophilia B},
   language = {eng},
   issn = {1538-7933},
   journal = {Journal of Thrombosis and Haemostasis},
   title = {Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH},
   url = {http://dx.doi.org/10.1111/jth.13867},
   volume = {15},
   year = {2017}
}

TY  - JOUR
ID  - 1399350
AU  - Iorio, A. - Blanchette, V. - Blatný, Jan - Collins, P. - Fischer, K. - Neufeld, E.
PY  - 2017
TI  - Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH
JF  - Journal of Thrombosis and Haemostasis
VL  - 15
IS  - 12
SP  - 2461-2465
EP  - 2461-2465
PB  - Wiley
SN  - 15387933
KW  - hemophilia A
KW  - hemophilia B
UR  - http://dx.doi.org/10.1111/jth.13867
L2  - http://dx.doi.org/10.1111/jth.13867
N2  - The ISTH SSC on Factor VIII/IX has previously issued guidelines for studies assessing the pharmacokinetics (PK) of factor concentrates [1, 2]. It suggested drawing 10 or 11 blood samples over a period of 32-48 h or 50-72 h, after infusing 25-50 IU kg-1 or 50-75 IU kg-1, respectively, for FVIII or FIX, in cohorts of 12-15 patients with a crossover design. Such PK studies are not ideal for tailoring the treatment of individual patients, mostly because of the requirement for several blood samples. Owing to broad interindividual variation, the individual disposition of FVIII and FIX cannot be predicted from morphometric characteristics and average PK parameters, but requires empirical assessment in each individual [3-6]. Previous guidance of this ISTH SSC described the PK methodology for the prediction of individual trough levels of FVIII [7]. The present communication, building on recent advances in the population pharmacokinetics (PopPK) of FVIII and FIX [8], adds to the former documents.
ER  -

IORIO, A., V. BLANCHETTE, Jan BLATNÝ, P. COLLINS, K. FISCHER and E. NEUFELD. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. \textit{Journal of Thrombosis and Haemostasis}. Hoboken: Wiley, 2017, vol.~15, No~12, p.~2461-2465. ISSN~1538-7933. Available from: https://dx.doi.org/10.1111/jth.13867.

Detailed Information on Publication Record